Application of blood plasma metabolites fingerprinting for the diagnostic of the 2nd stage of prostate cancer has been investigated. The diagnostic sensitivity (95%), specificity (96.7%) and accuracy (95.7%) of the metabolic fingerprinting were much higher then those for PSA test (35%, 83.3% and 51.7%, respectively) for the same patients. Area under the ROC-curve (0.994) suggests that the proposed approach is effective and can be used for clinical applications.